STOCK COMPARISON
Alteogen vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Alteogen (196170) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 293,500 versus a fair value of KRW 44,444 (-85%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).
Alteogen
196170.KQ · KRW · Health Care
-85%
upside to fair value
overvalued
PriceKRW 293,500
Fair ValueKRW 44,444
Quality53/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-42%
upside to fair value
overvalued
Price$484
Fair Value$279
Quality74/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
AlteogenVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
0.05×P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
0.1%Dividend yield—
KRW 371Dividend per share—
Profitability
64%Net margin36%
55%Operating margin38%
25%Return on equity24%
8%Return on assets12%
Growth
-15%Revenue growth (YoY)8%
95.7%Avg. growth/yr (3Y)10.6%
38.5%Avg. growth/yr (5Y)14.2%
Balance & size
0.01×Debt / equity0.03×
$10BMarket cap$123B
healthyGrowth qualityhealthy
Alteogen leads: 7 to 2 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Alteogenof which business quality 71 · market factors 16
Vertex Pharmaceuticalsof which business quality 77 · market factors 60
ProfitabilityMargins and returns on capital today
71
72
Quality GrowthAre margins and returns improving?
95
65
CashflowEarnings quality: real cash, not paper profit
72
79
Fin. StrengthBalance sheet, leverage, solvency risk
86
92
InvestmentDisciplined investing over empire-building
8
58
Low VolatilityCalm price path (market factor)
33
77
MomentumPrice trend over the last 3–12 months (market factor)
11
52
52W MomentumDistance to the 52-week high (market factor)
6
55
Net IssuanceBuybacks instead of dilution
74
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Alteogen
DCF ModelsKRW 53,584
Earnings-BasedKRW 92,661
MultiplesKRW 26,715
Asset-BasedKRW 5,574
Growth DCFKRW 43,022
Economic ProfitKRW 36,157
Growth EarningsKRW 119,401
24 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$429
Earnings-Based$516
Dividend Discount$7.07
Multiples$246
Asset-Based$49.27
Growth DCF$333
Economic Profit$254
Growth Earnings$672
19 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Alteogen
Bear KRW 26,767Fair Value KRW 44,444Bull KRW 59,426
KRW 293,500 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$484 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Alteogen · Health Care
Quality score53 · above median
Fair value upside-85% · bottom 25%
Vertex Pharmaceuticals · Health Care
Quality score74 · Top 25%
Fair value upside-42% · below median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 293,500 versus a fair value of KRW 44,444 (-85%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).
Vertex Pharmaceuticals has the higher quality score (74/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
